MajorDirect oral anticoagulants (factor Xa inhibitors)×Reversible P2Y12 receptor inhibitor
Updated · Methodology
Mechanism
Rivaroxaban is a highly selective direct inhibitor of coagulation factor Xa with no effect on platelets. Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation (rivaroxaban and ticagrelor summaries of product characteristics, SmPCs, European Medicines Agency, EMA). Platelet aggregation inhibitors increase the risk of bleeding on their own, and the risk rises further with rivaroxaban (rivaroxaban SmPC, EMA). Rivaroxaban 2.5 mg has not been studied in combination with ticagrelor (rivaroxaban 2.5 mg SmPC, EMA). Ticagrelor is a weak inhibitor of the CYP3A4 enzyme and of P-glycoprotein (P-gp). Drugs that strongly inhibit only one of these pathways raise rivaroxaban levels to a lesser extent than strong inhibitors of both (ticagrelor and rivaroxaban SmPCs, EMA).
Symptoms
The risk of overt or occult bleeding in any tissue or organ rises, up to fatal bleeding, together with the risk of post-haemorrhagic anaemia (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). With long-term rivaroxaban on top of single or dual antiplatelet therapy, mucosal bleeding is seen more often: nosebleeds, gum bleeding, gastrointestinal and genitourinary bleeding, including heavy menstrual bleeding, and anaemia (rivaroxaban 2.5 mg SmPC, EMA). Severe bleeding may be complicated by compartment syndrome or by kidney failure due to hypoperfusion (EMA).
Management
Rivaroxaban 2.5 mg twice daily has not been studied with ticagrelor, and the combination is not recommended. This dose was studied with acetylsalicylic acid alone or with acetylsalicylic acid plus clopidogrel or ticlopidine (rivaroxaban 2.5 mg summary of product characteristics, SmPC, European Medicines Agency, EMA). Treatment of an acute coronary syndrome with rivaroxaban 2.5 mg together with antiplatelet therapy is contraindicated in patients with a previous stroke or transient ischaemic attack (EMA). With other rivaroxaban doses, take care when platelet aggregation inhibitors are given concomitantly, and consider appropriate prophylactic treatment in patients at risk of ulcerative gastrointestinal disease (rivaroxaban 20 mg SmPC, EMA). Use ticagrelor with caution in patients who take oral anticoagulants within 24 hours of a ticagrelor dose (ticagrelor SmPC, EMA). There are no data on this combination, and the European Heart Rhythm Association practical guide (EHRA 2021) calls for careful monitoring. Observe the patient closely for signs of bleeding, look for a bleeding site if haemoglobin or blood pressure falls without explanation, and stop rivaroxaban if severe bleeding occurs (rivaroxaban SmPC, EMA). According to the US rivaroxaban label, promptly evaluate any sign or symptom of blood loss in patients who also take platelet aggregation inhibitors (rivaroxaban prescribing information, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Ticagrelor (EU/1/10/655), secciones 4.4 y 4.5 (2026)– EMA, ficha técnica de Brilique (EU/1/10/655) en CIMA, nº registro 10655004, texto vigente en CIMA a 03/10/2026, sin fecha de revisión, secciones 4.4 y 4.5
- EMA: Ficha técnica: Rivaroxabán, Xarelto 2,5 mg (EU/1/08/472), secciones 4.3 y 4.4 (2026)– EMA, ficha técnica de Xarelto 2,5 mg comprimidos recubiertos con película (Bayer AG), EU/1/08/472, texto en CIMA nº registro 108472027, consultado 02.11.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.8